Budesonide 

Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice.

≥99%

human ... IFNG(3458), IL5(3567)

rat ... Nr3c1(24413)

Stellato C., Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J. Immunol. 163, 5624, (1999) abstract

Wattenberg L.W., et al. Cancer Res. 57, 5489-92, (1997)

Szefler S.J., Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroid. J. Allergy Clin. Immunol. 104, 175, (1999) abstract

Adcock I.M., et al., Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NFκB and lack of IκB involvement. Br. J. Pharmacol. 127, 1003, (1999) abstract

Estensen R.D., et al. Carcinogenesis 25, 197-201, (2004)

Larsson S., Linden M., Effects of a corticosteroid, budesonide, on production of bioactive IL-12 by human monocytes. Cytokine 10, 786, (1998) abstract

3

TU3723000